-+ 0.00%
-+ 0.00%
-+ 0.00%

NeuroPace reports 82% median seizure reduction in 3-year RNS post-approval study

PUBT·04/27/2026 11:30:57
Listen to the news
NeuroPace reports 82% median seizure reduction in 3-year RNS post-approval study
  • NeuroPace published 3-year Post-Approval Study results in Neurology, reinforcing clinical benefit for its RNS System in drug-resistant focal epilepsy.
  • Data showed sustained seizure improvement in a broad, real-world adult population, supporting long-term use of responsive neurostimulation.
  • Separate NAUTILUS trial findings in idiopathic generalized epilepsy were already presented at American Academy of Neurology 2026, signaling expansion beyond focal epilepsy.
  • NAUTILUS results indicated meaningful seizure improvement with fewer seizure-related injuries, supporting a broader commercial opportunity for RNS in additional epilepsy populations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260423994564) on April 27, 2026, and is solely responsible for the information contained therein.